Alexander Starodub, MD
Hematology & Oncology · Cincinnati, OHNPI 1124087135
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,431 of the $71,626 with a category attached, or 74.6%. E.r. Squibb & Sons, L.L.C. accounts for 82.5% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $40,703 and has fallen 99.8% since, to $72 in 2025. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $596.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$59K
- Ascendis Pharma Endocrinology Inc$5K
- AstraZeneca$4K
- Bristol Myers Squibb$2K
- Novartis$165
- Gilead$138
- plus $1K from 26 others
Across 165 payments — averaging $6191.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$445K
- Ascendis Pharma Endocrinology Inc$288K
- AbbVie$89K
- Incyte Corporation$69K
- Merck$44K
- Biontech SE$21K
- plus $65K from 8 others
What the payments were for
- Consulting fees$9,55013%
- Speaking & faculty fees$53,43175%
- Travel & lodging$6,1539%
- Food & beverage$2,4223%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 52 | $59,102 |
| Ascendis Pharma Endocrinology Inc | 3 | $5,358 |
| AstraZeneca(2 entities) | 13 | $3,936 |
| Bristol Myers Squibb | 3 | $1,816 |
| Novartis | 8 | $165 |
| Gilead | 2 | $138 |
| Johnson & Johnson(2 entities) | 2 | $131 |
| Intera Oncology, Inc | 1 | $128 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $123 |
| Merck | 8 | $106 |
| Atricure, Inc. | 1 | $90 |
| Blueprint Medicines Corporation | 1 | $55 |
| Sanofi | 2 | $51 |
| Exelixis Inc. | 1 | $46 |
| Tactile Systems Technology Inc | 3 | $44 |
| Eisai Inc. | 2 | $34 |
| Amgen | 2 | $29 |
| Foundation Medicine, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Tempus AI, Inc | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Bayer | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Seagen Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$54,577
- IMFINZI$3,742
- INTERA$128
- IMBRUVICA$123
- Monarch Platform$111
How this compares
$71,626 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 41 | $609,291 |
| RozlytrekEntrectinib | 11 | $219,003 |
| EliquisApixaban | 54 | $38,877 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 65 | $1,562 |
| Oxycodone Hcl | 52 | $1,075 |
| Prochlorperazine Maleate | 70 | $941 |
| Granisetron Hcl | 16 | $925 |
| Ondansetron Hcl | 68 | $862 |
| Dexamethasone | 49 | $791 |
| Mirtazapine | 34 | $641 |
| Clobetasol Propionate | 12 | $601 |
| Pantoprazole Sodium | 40 | $507 |
| Morphine Sulfate ErMorphine Sulfate | 24 | $401 |
| Tamoxifen Citrate | 19 | $370 |
| Klor-Con 10Potassium Chloride | 21 | $357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Rozlytrek | $23 | $219,00311 claims |
| PfizerEliquis | $13 | $38,87754 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cincinnati
- David WaterhouseCincinnati$1.3M
- Mark AndolinaCincinnati$402K
- James EssellCincinnati$214K
- Akash MukherjeeCincinnati$132K
- Davendra SohalCincinnati$112K
- Edward FaberCincinnati$72K
- Brittaney Belle GordonCincinnati$53K
- Soumit BasuCincinnati$46K
- Trisha Wise-DraperCincinnati$44K
- Emily CurranCincinnati$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.